<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The incidence and prevalence of <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> (CD) and <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> (UC), the two major forms of <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel diseases</z:e> (IBD), are rising in western countries </plain></SENT>
<SENT sid="1" pm="."><plain>The modern hygienic lifestyle is probably at the root of a disease where, in genetically susceptible hosts, the intestinal commensal flora triggers dysregulated immune and <z:mp ids='MP_0001845'>inflammatory responses</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Current therapies ranging from <z:chebi fb="3" ids="35472">anti-inflammatory drugs</z:chebi> to immunosuppressive regimens, remain inadequate </plain></SENT>
<SENT sid="3" pm="."><plain>Advances in our understanding of the cell populations involved in the pathogenetic processes and recent findings on the regenerative, trophic and immunoregulatory potential of stem cells open new paths in IBD therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Hematopoietic and mesenchymal stem cells are catalyzing the attention of IBD investigators </plain></SENT>
<SENT sid="5" pm="."><plain>This review highlights the pivotal findings for stem cell-based approaches to IBD therapy and collects the encouraging results coming in from clinical trials </plain></SENT>
</text></document>